# Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19

> **NCT07416539** · PHASE1 · RECRUITING · sponsor: **Rokote Laboratories Finland Oy** · enrollment: 20 (estimated)

## Conditions studied

- COVID - 19
- SARS CoV-2

## Interventions

- **BIOLOGICAL:** COVID-19 Vaccines
- **BIOLOGICAL:** COVID-19 Vaccines

## Key facts

- **NCT ID:** NCT07416539
- **Lead sponsor:** Rokote Laboratories Finland Oy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-10
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-20

## Collaborators

- Oy Medfiles Ltd
- Estimates OY

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07416539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07416539, "Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT07416539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*